布地奈德/治疗应用

摘要： [目的]探讨布地奈德联合气管插管-肺表面活性物质-拔管使用持续气道正压通气技术(INSURE)在早产儿呼吸窘迫综合征的应用价值.[方法]回顾性分析2018年1月至2019年12月本院收治的30例N RDS早产儿的临床资料,根据治疗方法的不同将其分为观察组和对照组,每组各15例.两组均应用INSURE技术治疗,观察组联合应用布地奈德.比较两组患儿血气分析指标,肺表面活性物质(PS)再次使用率、平均撤机时间、平均总吸氧时间、支气管肺发育不全(BPD)发生率及严重程度,并记录比较两组患儿治疗期间并发症发生情况.[结果]给药后12 h、24 h,两组患儿pH、血氧分压(PaO2)水平均高于给药后4 h,且观察组高于对照组;两组患儿二氧化碳分压(PaCO2)水平低于给药后4 h,且观察组低于对照组,差异均有统计学意义(均P0.05).[结论]布地奈德联合INSURE技术应用于早产儿呼吸窘迫综合征治疗中可有效改善患儿血气指标,提高治疗效果,减少早产儿BPD发生,未增加治疗期间并发症的风险,值得推广应用.

摘要： [目的]探讨布地奈德雾化吸入治疗早产儿支气管肺发育不良(BPD)的疗效.[方法]回顾性分析92例本院诊治的BPD的早产儿临床资料,按照治疗方法分为布地奈德组29例、地塞米松组34例、对照组29例(未使用糖皮质激素).[结果]治疗后,与对照组相比,布地奈德组和地塞米松组的BPD分度较轻;但布地奈德组和地塞米松组比较差异无统计学意义(P>0.05).对照组的输氧时间、使用无创机械通气时间均显著高于地塞米松组和布地奈德组,其差异具有统计学意义(P0.05).三组脓毒血症、动脉导管未闭(HsPDA)、脑室内出血(IVH)≥ Ⅲ级、脑白质软化(PVL)、坏死性小肠结肠炎(NEC)、消化道出血、肺动脉高压(PPHN)、高血糖发生率比较差异均无统计学意义(P>0.05).[结论]对于需持续用氧或使用呼吸机的早产儿,早期(≥14 d)使用布地奈德雾化吸入对其BPD有治疗的作用,可减少患儿用氧时间和机械通气时间,避免患儿全身使用糖皮质激素,且未见近期不良并发症,但远期预后仍需进一步研究.

摘要： 目的 探讨和分析布地奈德联合特布他林在儿童支气管哮喘中的临床应用价值.方法 选择2017年1-12月该院收治的支气管哮喘患儿100例,采用随机数字表法分为观察组(51例)和对照组(49例).对照组给予特布他林治疗,观察组给予布地奈德联合特布他林治疗,比较和分析两组患儿的临床疗效 、症状消失时间及不良反应发生情况.结果 与对照组比较,观察组患儿显效率 、总有效率均明显提高,无效率明显降低,咳嗽消失时间 、喘憋消失时间 、呼吸困难消失时间 、哮鸣音消失时间均明显缩短,差异均有统计学意义(P0.05).结论 支气管哮喘患儿经布地奈德与特布他林的联合治疗后临床症状得到及时好转,疗效得到全面提升.

摘要： [Objective]To study the efficacy of budesonide combined with nasal endoscopic surgery in the treatment of refractory rhinosinusitis(RRS)and the effect on mucosal tissue remodeling.[Methods] Sixty-eight patients with RRS treated in our hospital during November 2013-November 2016 were randomly divided into the control group and the observation group,34 cases in each group.The control group was treated by corrective nasal endoscopic surgery while the observation group was additionally treated with budesonide.The efficacy and effect on mucosal tissue remodeling were compared between the two groups.[Results] The operation time,intraoperative blood loss and operative field bleeding score of the observation group were significantly shorter,less and lower than those of the control group(P ＜ 0.05).The total effective rate in the observation group was significantly higher than that in control group(94.12％vs 76.47％)(P ＜0.05).After treatment,the scores of nasal obstruc-tion,runny nose,olfactory injury,head pain and visual simulated pain were significantly decreased in the two groups(P ＜0.05).Lund-Kennedy score decreased significantly(P ＜0.05).Nasal mucosal injury was signifi-cantly improved(P ＜0.05).The positive ratio of TGF-β1 and the proportion of collagen Ⅲ positive basement membrane thickness＞20μm were significantly reduced(P ＜0.05),and the improvement amplitude of the obser-vation group was greater than that of the control group(P ＜0.05);6 months after operation,the total incidence of complications in the observation group was 11.76％and the recurrence rate was 5.88％,which was significantly lower than that in the control group(26.47％and 23.53％,P ＜0.05).[Conclusion] Application of budesonide in corrective nasal endoscopic surgery for RRS can significantly shorten the operation time,reduce blood loss,inhibit the nasal mucosa remodeling,decrease postoperative complications and recurrence,and improve the prognosis.%[目的]研究布地奈德联合鼻内镜手术治疗难治性鼻-鼻窦炎(RRS)的疗效及对黏膜组织重塑的影响.[方法]选择2013年11月至2016年11月于本院接受治疗的68例RRS患者,随机分为对照组及观察组各34例.对照组行修正性鼻内镜手术治疗,观察组加用布地奈德治疗,比较两组疗效及对黏膜组织重塑的影响.[结果]观察组手术时间、术中出血量、术野出血评分均显著少于对照组(P＜0.05);观察组治疗总有效率为94.12％,显著高于对照组的76.47％(P＜0.05);治疗后两组鼻塞、流涕、嗅觉损伤、头面疼痛视觉模拟疼痛(VAS)评分显著降低(P＜0.05),Lund-Kennedy评分显著降低(P＜0.05),鼻腔黏膜损伤得到明显改善(P＜0.05),TGF-β1阳性率和胶原Ⅲ阳性基底膜厚度＞20μm构成比显著降低(P＜0.05),且观察组改善幅度大于对照组(P＜0.05);术后6个月,观察组并发症总发生率11.76％,复发率5.88％,显著低于对照组的26.47％和23.53％(P＜0.05).[结论]布地奈德联合鼻内镜手术治疗难治性鼻窦炎,可明显缩短手术时间,减少出血量,抑制鼻腔黏膜重塑,降低术后并发症和复发风险,改善预后.

摘要： 目的:观察穴位刺激联合吸入疗法对小儿哮喘患者症状体征及呼吸功能状态的影响情况.方法:选取哮喘患儿为研究对象,将患儿随机分为两组,对照组的32例患儿进行常规西药吸入治疗,观察组的32例患儿则在对照组的基础上加用穴位刺激治疗,然后将两组患儿的症状体征改善时间、治疗前后不同时间点的呼吸功能状态指标进行比较.结果:观察组患儿的气促缓解时间、喘憋消失时间及哮鸣音消失时间<3 d者比例分别为87.50%、78.13% 及71.88%,均高于对照组患儿的56.25%、50.00% 及43.75%,治疗后不同时间点的常见肺功能指标及气道反应指标等呼吸功能状态指标均显著地好于对照组患儿,P均<0.05,两组患儿间均有显著性差异.结论:穴位刺激联合吸入疗法可有效地改善小儿哮喘患者的症状体征,且对呼吸功能状态的改善作用也十分突出.%Objective:To observe the influence situation on acupoint stimulation combined with anapnotherapy for the sings and symptoms,respiratory function state of children with asthma.Methods:64 children with asthma were the study object,and 64 children were randomly divided into two groups,32 children of control group were trea-ted with conventional anapnotherapy of western medicine,32 children of observation group were treated with acupoint stimulation on the treatment of control group,then the important time of sings and symptoms,respiratory function state indexes at different time before and after the treatment of two groups were compared.Results:The rates of re-mission time of breath shortness,disappearing time of asthmatic suffocating and disappearing time of wheeze rale <3 d of observation group were respectively 87.50%,78.13 and 71.88%,and they were all higher than 56.25%,50. 00% and 43.75% of control group,the respiratory function state indexes including common lung function indexes and airway response indexes at different time after the treatment were all significantly better than those of control group,all P<0.05,the two groups' differences were all significant.Conclusion:The acupoint stimulation combined with anapnotherapy can effectively improve the sings and symptoms of children with asthma,and the improvement role for the respiratory function state is prominent,so the application value of the treatment program in theses chil-dren is higher.

摘要： Objective:To investigate the clinical efficacy of nasal endoscopic surgery combined with budes-onide nasal inhalation in the treatment of nasal polyps and its impact on the quality of life of patients.Methods:A to-tal of 132 patients with nasal polyps treated in our hospital in March September 2015-2018 were selected as the re-search subjects.They were randomly divided into the control group (n＝66) and the study group (n＝66) according to the digital table method.The control group was treated with nasal endoscopy,and the study group was treated with nasal endoscopic surgery combined with budesonide nasal atomization inhalation treatment.Compared to the two groups,the clinical effect,the VAS score (pain score),the LKES score (endoscopy score),the expression level of VEGF,GM-CSF,IL-1 beta,IFN-gamma in the nasal mucosa before and after treatment,and the quality of life of the patients before and after treatment were compared.Results:After treatment,the treatment and efficiency of the patients in the study group were significantly higher than those of the control group (P＜0.05).Before treat-ment,there was no significant difference in the VAS score between the two groups.After the treatment,the VAS score of the patients in the study group was significantly lower than that of the control group (P ＜ 0.05) ;the LKES score of the two groups was not significantly worse before the treatment.After treatment,the LKES score of the patients in the study group was significantly lower than that of the control group (P＜0.05).Before treatment,the expression levels of VEGF,GM-CSF,IL-1 beta and IFN-gamma in the nasal mucosa of the two groups were not significantly different (P＞0.05).After treatment,the expression level of VEGF,GM-CSF,IL-1 beta and IFN-gamma in the nasal mucosa of the study group was obvious.Lower than the control group (P＜0.05) ;before treat-ment,the quality of life of the two groups had no significant difference (P＞0.05).After treatment,the quality of life of the patients in the study group was significantly higher than that of the control group (P＜0.05).Conclusion:the clinical efficacy of nasal endoscopic surgery combined with budesonide nasal atomization inhalation in the treat ment of nasal polyps Obviously,high safety,significant improvement in the quality of life of patients,worthy of fur-ther clinical application.%目的:探讨鼻内镜手术联合布地奈德鼻喷雾剂治疗鼻息肉的临床疗效及对患者生活质量的影响.方法:鼻息肉患者共132例,按照数字表法随机分为对照组(n＝66)和研究组(n＝66) ,对照组给予鼻内镜手术治疗,研究组给予鼻内镜手术联合布地奈德鼻喷雾剂治疗,对比两组患者在治疗后的临床效果、VAS评分(疼痛评分) 、LKES评分(内镜评分) 、治疗前后鼻黏膜中VEGF 、GM-CSF 、IL-1β 、IFN-γ的表达水平以及治疗前后患者的生活质量.结果:研究组患者的治疗有效率明显高于对照组患者(P＜0.05) ;研究组患者的VAS评分明显低于对照组患者(P＜0.05) ;研究组患者的LKES评分明显低于对照组(P＜0.05) ;治疗前,两组患者鼻黏膜中的VEGF 、GM-CSF 、IL-1β 、IFN-γ的表达水平无统计学差异(P＞0.05) ,治疗后,研究组患者鼻黏膜中的VEGF 、GM-CSF 、IL-1β 、IFN-γ的表达水平明显低于对照组患者(P＜0.05) ;治疗前,两组患者的生活质量评分无统计学差异(P＞0.05) ,治疗后,研究组患者的生活质量明显高于对照组患者(P＜0.05).结论:鼻内镜手术联合布地奈德鼻喷雾剂治疗的临床疗效明显,安全性高,对患者的生活质量具有显著的改善作用,值得在临床上进一步推广应用.

摘要： Objective:To investigate the effect of Budesonide suspension nasal inhalation of antibiotics on si-nusitis in children .Methods :80 cases of sinusitis were randomly divided into two groups ,40 cases in the control group were treated by amoxicillin clavulanate potassium sequential therapy ,and 40 cases in the treatment group were treated by budesonide suspension inhalation and amoxicillin clavulanate potassium sequential therapy .The clinical Symptomatic subjective score ,CT score and clinical efficacy were compared between the two groups .Results :After the treatment ,the nasal congestion ,runny nose ,headache ,breath odor and CT scores in the two groups were sig-nificantly lower than those before treatment (P<0 .05) ,and which in the treatment group were significantly lower than those in the control group (P<0 .05) .The clinical efficacy in the treatment group was significantly better than that in the control group (P<0 .05) .Conclusion :Budesonide suspension nasal aerosol inhalation assisted antibiotic treatment of children with sinusitis safe and effective .%目的:探讨布地奈德混悬液鼻腔雾化吸入辅助抗生素治疗儿童鼻窦炎的疗效.方法:随机将80例鼻窦炎患儿分为两组,对照组40例采取阿莫西林克拉维酸钾序贯疗法,治疗组40例在对照组治疗基础上加用布地奈德混悬液吸入,比较两组临床症状主观评分、CT评分及临床疗效.结果:两组患儿治疗后鼻塞、流涕、头痛、呼吸有臭味评分及CT评分均较治疗前明显降低(P<0.05),治疗组明显低于对照组(P<0.05).治疗组临床疗效明显优于对照组(P<0.05).结论:布地奈德混悬液鼻腔雾化吸入辅助抗生素治疗儿童鼻窦炎安全、有效.

摘要： 目的 探讨噻托溴铵联合布地奈德(BUD)治疗哮喘-慢阻肺重叠综合征(ACOS)患者的临床效果.方法 选取2014年1月至2016年3月本院收治的94例ACOS患者进行研究,采用随机数字表法分为联合组和对照组各47例,对照组47例患者单用噻托溴铵治疗,联合组47例患者采用噻托溴铵+布地奈德(BUD)治疗,两组疗程均为8周.检测并对比两组患者治疗前后的肺功能指标、哮喘症状评分(ACT)、慢性阻塞性肺疾病症状评分(CAT)及外周血中T淋巴细胞亚群.结果 治疗前,两组患者的第一秒用力呼气容积(FEV1)、FEV1/FVC(最大肺活量)、吸气分数[IC/TLC(％)]测定值比较差异无统计学意义(P＞0.05);治疗后,联合组患者的FEV1、FEV1/FVC、IC/TLC(％)测定值均高于对照组(P＜0.05);治疗前,两组患者的CD3+、CD4+、CD8+、CD4 +/CD8+、ACT、CAT评分比较差异无统计学意义(P＞0.05);治疗后,联合组患者的CD3+、CD4+、CD4 +/CD8+、ACT评分均高于对照组(P＜0.05),CD8+、CAT评分显著低于对照组(P＜0.05).结论 噻托溴铵联合BUD治疗ACOS患者效果更显著,可进一步改善ACT、CAT评分及患者免疫水平.

摘要： 目的:分析总结小儿支原体感染后咳嗽治疗中应用肺炎合剂联合阿奇霉素口服及雾化吸入的治疗效果.方法:以随机数字表法,将80例小儿支原体感染后咳嗽患儿分为两组,以接受包括阿奇霉素口服及布地奈德、异丙托溴铵溶液雾化吸入的西药治疗者为对照组,在以上治疗基础上加用肺炎合剂口服为治疗组,每组40例.对比两组临床治疗效果.结果:接受治疗2周后,治疗组支原体滴度≥1:160例数低于对照组(P0.05).结论:肺炎合剂联合布地奈德可显著的改善小儿支原体感染后咳嗽的治疗效果.

摘要： 目的:探讨布地奈德混悬液雾化及万托林雾化两种吸入治疗方案对小儿咳嗽变异性哮喘的临床疗效.方法:选择小儿咳嗽变异性哮喘患者216例,分为两组.其中万托林组患者接受万托林雾化吸入治疗,布地奈德混悬液组在以上基础上,加布地奈德混悬液雾化吸入治疗.分别测定研究对象临床症状的恢复、肺功能改善、治疗效果评分、患儿家属满意度及不良反应情况.结果:布地奈德混悬液组患者哮喘持续时间、哮鸣音和咳嗽消失时间均明显小于万托林雾化组(P<0.05);治疗后,布地奈德混悬液组患者肺功能指标最大空气峰流速为(1.583±0.512)L/min,优于万托林雾化组的(1.254±0.371)L/min;布地奈德混悬液组患者治疗效果评分为167,远高于万托林组(P<0.05);布地奈德混悬液组患儿家属满意度95.37%,远高于万托林组(P<0.05);两组患者均未出现明显不良反应.结论:布地奈德混悬液吸入治疗方案可有效缓解患者病情 ,提高患者临床疗效和满意度 ,且未见不良反应.

摘要： 本发明涉及由患者根据需要使用的、用于缓解症状的组合物在制备预防或治疗急性气喘和/或间歇性气喘和/或慢性气喘偶发用药物中的应用，在混合物中含有(a)第一种活性成分，为福莫特罗、其可药用盐或其溶剂化物或所述盐的溶剂化物；和(b)第二种活性成分，为布地奈德。本发明还涉及预防或治疗急性气喘和/或间歇性气喘和/或慢性气喘偶发的方法，包括通过吸入法施用如上定义的含有第一种和第二种活性成分的组合物。

摘要： 本发明涉及匹多莫德或其生理学上可接受的盐治疗特应性皮炎的用途。对于本发明的治疗，优选局部施用匹多莫德或其生理学上可接受的盐。

摘要： 本发明涉及匹多莫德或其生理学上可接受的盐用于治疗银屑病的用途。对于本发明的治疗，可以全身或局部施用匹多莫德或其生理学上可接受的盐。

摘要： 本发明提供一种治疗罹患活动性狼疮关节炎的个体的方法，其包含向所述个体周期性投与有效治疗所述个体的量的拉喹莫德（laquinimod）或其药学上可接受的盐。本发明还提供用于治疗罹患活动性狼疮关节炎的个体的拉喹莫德或其药学上可接受的盐。本发明进一步提供一种药物组合物，其包含一定量的拉喹莫德或其药学上可接受的盐，以用于治疗罹患狼疮关节炎的个体。

摘要： 本发明涉及用于缓解需缓解症状的组合物在制备预防或治疗急性气喘和/或间歇性气喘和/或慢性气喘偶发用药物中的应用,在混合物中含有(a)第一种活性成分,为福莫特罗、其可药用盐或其溶剂化物或所述盐的溶剂化物;和(b)第二种活性成分,为布地奈得。本发明还涉及预防或治疗急性气喘和/或间歇性气喘和/或慢性气喘偶发的方法,包括通过吸入法施用如上定义的含有第一种和第二种活性成分的组合物。

摘要： 本发明涉及用阿吡莫德治疗癌症的方法以及相关组合物和方法。

摘要： 本公开内容涉及使用阿吡莫德在具有过度表达小眼(MiT)转录因子的癌细胞的受试者中治疗癌症的组合物和方法，以及相关的组合物和方法。

摘要： 本发明提供用于降低复发缓解型多发性硬化人类患者的复发率和/或减少其身体残疾积累的方法，所述方法包含向患者经口投予0.6mg日剂量的拉喹莫德(laquinimod)。本发明还提供0.6mg拉喹莫德的医药口服单位剂型，其用于降低复发缓解型多发性硬化人类患者的复发率和/或用于减少其身体残疾积累。

摘要： 本发明提供一种治疗患有视网膜神经节细胞(RGC)损失或损伤或眼内压(IOP)升高的患有青光眼的个体的方法，或减轻个体的RGC损失或损伤或者降低IOP的方法，其包括向所述个体施用有效治疗所述个体的量的拉喹莫德，从而减轻所述个体的RGC损失或损伤，或者降低IOP。还提供了用于治疗患有青光眼的个体的药物组合物、包装以及治疗包装。

摘要： 本申请提供了一种治疗患有克隆氏病(Crohn’s？diesease)受试者的方法，该方法包括定期向受试者给药适量的拉喹莫德(laquinimod)或其药用可接受的盐，从而有效治疗受试者。本申请提供了拉喹莫德在制备用于治疗患有克隆氏病受试者的药物中的用途。本申请还提供了一种包含拉喹莫德的药用组合物，该组合物用于治疗患有克隆氏病的受试者。